Alto Neuroscience Inc., a clinical-stage biopharmaceutical company, has announced positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept trial of ALTO-203. The study focused on patients with major depressive disorder exhibiting elevated levels of anhedonia. ALTO-203, an oral, non-stimulant histamine H3 inverse agonist, has demonstrated effects on cognition, wakefulness, and alertness. The trial identified the theta/beta ratio as a significant pharmacodynamic marker, with ALTO-203 reducing this EEG index associated with attentional control compared to placebo. While patients reported improvements in alertness and mood, a higher-than-expected placebo response was noted, with no significant separation from ALTO-203 on subjective assessments. These results replicate findings from a Phase 1 study and underscore the potential of ALTO-203 in precision psychiatry. Results have already been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.